Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8NB59
UPID:
SYT14_HUMAN
Alternative names:
Synaptotagmin XIV
Alternative UPACC:
Q8NB59; B1AJU0; B1AJU1; F5H426; Q5THX7; Q707N3; Q707N4; Q707N5; Q707N6; Q707N7
Background:
Synaptotagmin-14, also known as Synaptotagmin XIV, plays a crucial role in the trafficking and exocytosis of secretory vesicles in non-neuronal tissues, operating independently of Ca(2+). This protein's unique function is pivotal in cellular communication and the release of secretory substances.
Therapeutic significance:
Spinocerebellar ataxia, autosomal recessive, 11 (SCAR11) is directly linked to mutations affecting Synaptotagmin-14. This connection highlights the protein's significant role in neurological disorders, specifically those involving cerebellar degeneration and psychomotor retardation. Understanding the role of Synaptotagmin-14 could open doors to potential therapeutic strategies for SCAR11.